These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 17697328)

  • 1. Clinical decision modeling system.
    Shi H; Lyons-Weiler J
    BMC Med Inform Decis Mak; 2007 Aug; 7():23. PubMed ID: 17697328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
    Mortensen MB
    Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using decision analysis to assess comparative clinical efficacy of surgical treatment of unstable ankle fractures.
    Michelson JD
    J Orthop Trauma; 2013 Nov; 27(11):642-8. PubMed ID: 23481924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial intelligence framework for simulating clinical decision-making: a Markov decision process approach.
    Bennett CC; Hauser K
    Artif Intell Med; 2013 Jan; 57(1):9-19. PubMed ID: 23287490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It is money that matters: decision analysis and cost-effectiveness analysis.
    Kocher MS; Henley MB
    Clin Orthop Relat Res; 2003 Aug; (413):106-16. PubMed ID: 12897601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of R in Health Decision Sciences.
    Jalal H; Pechlivanoglou P; Krijkamp E; Alarid-Escudero F; Enns E; Hunink MGM
    Med Decis Making; 2017 Oct; 37(7):735-746. PubMed ID: 28061043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation and evaluation of an Asbru-based decision support system for adjuvant treatment in breast cancer.
    Eccher C; Seyfang A; Ferro A
    Comput Methods Programs Biomed; 2014 Nov; 117(2):308-21. PubMed ID: 25063336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysis.
    Søgaard R; Fischer BM; Mortensen J; Rasmussen TR; Lassen U
    Value Health; 2013; 16(1):57-65. PubMed ID: 23337216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness Analysis of Treatment Options for Single Brain Metastasis.
    Kimmell KT; LaSota E; Weil RJ; Marko NF
    World Neurosurg; 2015 Nov; 84(5):1316-32. PubMed ID: 26100168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002-2021.
    Hunter DJ; Drake SM; Shortt SE; Dorland JL; Tran N
    Cancer Detect Prev; 2004; 28(6):453-60. PubMed ID: 15582269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision analysis for the cost effectiveness of sestamibi scintimammography in minimizing unnecessary biopsies.
    Allen MW; Hendi P; Schwimmer J; Bassett L; Gambhir SS
    Q J Nucl Med; 2000 Jun; 44(2):168-85. PubMed ID: 10967626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial.
    Krijkamp EM; Alarid-Escudero F; Enns EA; Jalal HJ; Hunink MGM; Pechlivanoglou P
    Med Decis Making; 2018 Apr; 38(3):400-422. PubMed ID: 29587047
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.